维普期刊资源整合服务平台（V6.5）

118篇 您的检索式：作者名="Pegram MD"

选中清除导出查看参考文献查看引证文献引用追踪共6页首页上一页第1页下一页末页 /6 跳转

	题名	作者	年代	出处	被引量
1	Antibody-dependent cell mediated cytotoxicity in breast cancer patients in phase Ⅲ clinical trials of a humanized anti-HER2 antibody显示文摘	Pegram MD Baly D Wirth C	1997	Proc Am Assoc Cancer Res1997，38，：	1
2	Trastuzumab and chemotherapeutics: drug interactions and synergies 显示文摘	Pegram MD Lopez A Konecny G	2000	Semin Oncol2000，27，611：	1
3	Rational combinations of trasruzumab with chemotherapeutic drugs used in the treatment of breast cancer 显示文摘	Pegram MD Konecny GE O'Callaghan C	2004	J Natl Cancer Inst2004，96，10：	1
4	Emission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA- reactive drugs 显示文摘	Pietras RJ Pegram MD Finn RS	1998	Oncogene1998，17，17：	1
5	HER-2/neu as a predictive marker of response to breast cancer therapy显示文摘	Pauletti G Slamon DJ	1998	Breast Cancer Res Treat1998，52，13：	1
6	Phase Ⅰ dose escalation pharmacokinetic assessment of intravenous humanized anti-MUC1 antibody AS1402 in patients with advanced breast cancer显示文摘	Pegram MD Borges VF Ibrahim N	2009	Breast Cancer Res2009，11，5：	1
7	Effect of erbB2 over expression on chemotherapeutic drug sensiti vity in human breast ovarian cancer cells显示文摘	Pegram MD	1993	Am Assoc Cancer Res1993，34，：	1
8	Results of two open-label multicenter phase Ⅱ studies of docetaxel platinum salts and trastuzumab in HER2-positive advanced breast cancer显示文摘	Pegram MD Pienkowski T Northfelt DW	2004	J Natl Cancer Inst2004，96，10：	1
9	Results of two open-label, muhicenter phase Ⅱ studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer显示文摘	Pegram MD Pienkowski T Northfeh DW	2004	J Natl Cancer Inst2004，96，10：	1
10	Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs显示文摘	Pietras R J Pegram MD Finn RS	1998	Oncogene1998，17，8：	1
11	The effect of Her2/neu overexpression on cllemolherapeutie drug sensitivity in human breast and ovarian cancer eells显示文摘	Pegram MD Finn RS Arzoo K	1997	Oncogene1997，15，：	1
12	HER-2/neu as a predictive marker of response to breast cancer therapy 显示文摘	Pegram MD Psuletti G Slamon DJ	1998	Breast Caner Res Treat1998，52，13：	1
13	Activity of the Dual Kinase Inhibitor Lapatinib (GW572016) against HER-2-Overexpressing and Trastuzumab-Treated Breast Cancer Cells 显示文摘	Konecny GE Pegram MD Venkatesan N	2006	Cancer Research2006，66，3：	1
14	Activity of the dual kinase inhibitor lapatinib ( GW572016 ) against HER - 2 - overexpressing and trastuzumab- treated breast cancer cells 显示文摘	Konecny GE Pegram MD Venkatesan N	2006	Cancer Res2006，66，：	1
15	Treating the HER2 pathway in early and advanced breast cancer 显示文摘	Pegram MD	2013	Hematol Oncol Clin North Am2013，27，4：	1
16	Therapeutic advantage of chemotherapy drugs in combination with Herceptin against human breast cancer cells with HER-2/neu overexpression 显示文摘	Konecny G Pegram MD Beryt M	1999	Breast Cancer Res Treat1999，57，：	1
17	Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer 显示文摘	Pegram MD Konecny GE O'Callaghan C	2004	J Natl Cancer Inst2004，96，10：	1
18	Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer显示文摘	Pegram MD Konecny GE Callagham CO	2004	Natl Cancer Inst2004，9，6：	1
19	Phase I dose escalation pharmacokinetic assessment of intravenous humanized anti-MUC1 an- tibody AS1402 in patients with advanced breast cancer显示文摘	Pegram MD Borges VF Ibrahim N	2009	Breast Cancer Res2009，11，5：	1
20	Activity of the dual kinase inhibitor lapatinib (GW572016) against Her-2 overexpressing and trastuzumab treated breast cancer cells显示文摘	Konecny GE Pegram MD Venkatesan N	2006	Cancer Res2006，66，3：	1

返回顶部每页显示：

共6页首页上一页第1页下一页末页 /6 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示